Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. reports developments as a clinical-stage siRNA biopharmaceutical company advancing its proprietary INTASYL® gene-silencing technology for immuno-oncology. Company updates center on PH-762, an INTASYL compound designed to silence the PD-1 gene and evaluated as an intratumoral therapy for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Recurring news themes include PH-762 clinical results, safety and pathology data, nonclinical toxicology work, cGMP clinical-supply manufacturing, regulatory-development steps, financial results, equity financing activity and investor presentations. Coverage also reflects the company's use of self-delivering RNAi technology intended to enhance immune-cell activity against tumor cells without specialized formulation or delivery systems.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced its CEO, Dr. Gerrit Dispersyn, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9, and can be accessed through the company's website. Phio is focused on advancing its proprietary self-delivering RNAi therapeutic platform, INTASYL™, aimed at treating cancer by enhancing immune response against tumor cells.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has successfully completed a registered direct offering of 2,246,784 shares of common stock at $3.42 per share, yielding gross proceeds of approximately $7.7 million. The funds will primarily support working capital needs and the advancement of its immuno-oncology programs. The offering was conducted under a shelf registration statement declared effective by the SEC in 2018. H.C. Wainwright & Co. served as the placement agent for this offering.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced a registered direct offering of 2,246,784 shares of common stock priced at $3.42 per share, raising approximately $7.7 million. The offering is expected to close around February 17, 2021, pending customary closing conditions. The funds will primarily support general working capital, including the development of immuno-oncology programs. H.C. Wainwright & Co. serves as the exclusive placement agent. The shares are offered under an effective shelf registration statement.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the closing of a private placement, issuing 4,560,928 shares at $3.07 each, alongside warrants for 3,420,696 shares. This transaction raised approximately $14.0 million before expenses. The company plans to use the funds for its immuno-oncology research and general working capital. The warrants have an exercise price of $3.00 and are valid for five and a half years. Phio must file a registration statement covering the resale of the shares by February 1, 2021.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced a private placement to raise approximately $14.0 million by issuing 4,560,928 shares of common stock at $3.07 per share, along with warrants for 3,420,693 shares at an exercise price of $3.00. The placement is expected to close around January 25, 2021. Proceeds will be used for the development of immuno-oncology programs and general working capital. The company is required to file a registration statement within ten days for the resale of shares issued to investors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Dr. Gerrit Dispersyn's corporate presentation will be available on-demand starting at 6 a.m. ET on January 11, 2021. The webcast can be accessed through the Company’s website and will be archived for 90 days. Phio focuses on advancing immuno-oncology therapeutics using its self-delivering RNAi platform, INTASYL™, aimed at tackling tumor-induced immune suppression.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology firm focused on immuno-oncology, announced that CEO Dr. Gerrit Dispersyn will present at the 3rd Annual Evercore ISI HealthCONx Conference, held virtually from December 1-3, 2020. Dr. Dispersyn's fireside chat is scheduled for December 3 at 3:05 p.m. ET, accessible via a live webcast. Phio's proprietary INTASYL™ RNAi platform aims to enhance immune responses against tumors. More details and a recorded version will be available on the company’s website post-event.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q3 2020, ending with $16.9 million in cash, up from $6.9 million in December 2019. The company increased R&D expenses to $1.3 million, attributed to preclinical studies. The net loss for the quarter was $2.3 million, or $0.40 per share, slightly higher than the $2.1 million net loss from the same quarter last year. Phio presented promising data at SITC 2020, showcasing its INTASYL RNAi technology's potential in enhancing cancer immunotherapy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising results from a recent in vivo study demonstrating the enhanced efficacy of its INTASYL pipeline products when combined. The data, presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer, shows that combining INTASYL compounds significantly improves tumor control compared to monotherapy. The compounds target PD-1, PD-L1, and TIGIT proteins linked to immune suppression in cancer. These findings suggest a potential breakthrough in the treatment of solid tumors, increasing the therapeutic options available for patients.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced three upcoming poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), occurring virtually from November 9-14, 2020. The poster presentations highlight INTASYL compounds, a proprietary self-delivering RNAi therapeutic platform. Notably, findings include a study on combination treatment using INTASYL targeting TIGIT and PD-1/PD-L1, revealing enhanced tumor control. The archived presentation will be accessible in the "Investors – Events and Presentations" section of the Company's website.